Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (CERS) is a pioneering biomedical products company dedicated to enhancing blood safety worldwide. The company’s flagship technology, the INTERCEPT Blood System, aims to mitigate the risk of transfusion-transmitted diseases by inactivating a broad spectrum of pathogens, including viruses, bacteria, and parasites present in donated blood. Utilizing a unique nucleic acid targeting mechanism, the INTERCEPT system offers protection against established threats like Hepatitis B and C, HIV, West Nile Virus, and bacteria, while also being designed to inactivate emerging pathogens such as Influenza, Malaria, and Dengue.
Cerus Corporation markets and sells the INTERCEPT Blood System for both platelets and plasma in various regions including Europe, Russia, the Middle East, and selected countries globally. The INTERCEPT Red Blood Cell system is currently in clinical development, highlighting the company’s ongoing efforts to broaden its product offerings and enhance blood safety further.
Recent achievements for Cerus include expanding market reach, securing regulatory approvals, and forging key partnerships to strengthen its global presence. Financially, Cerus remains focused on sustaining growth through innovation and strategic collaborations.
By prioritizing safety and efficacy, Cerus Corporation plays a critical role in the field of blood transfusion safety, making significant strides in protecting public health on a global scale.
Cerus Corporation (Nasdaq: CERS) has announced that CEO William ‘Obi’ Greenman and CFO Kevin D. Green will participate in two upcoming conferences. The first event is the BTIG Virtual MedTech Conference on February 17 at 1:30 PM ET, followed by the Cowen 41st Annual Health Care Conference on March 1 at 2:40 PM ET. Both events will be webcast live, with replays available for two weeks post-event. Cerus focuses on enhancing blood safety through its INTERCEPT Blood System, which has received both CE mark and FDA approval for pathogen reduction in platelets and plasma.
Cerus Corporation (Nasdaq: CERS) reported preliminary product revenue for Q4 2020 at $28.2 million, a 35% increase from $20.9 million in Q4 2019, which positions it for a total 2020 revenue of $91.9 million. This is above the prior guidance range of $89 million to $91 million. The company anticipates 2021 revenue of $106 million to $110 million, reflecting 15% to 20% growth driven by strong demand for INTERCEPT platelet kits despite ongoing COVID-19 impacts. Additionally, 2021 will see the first sales of a new biologic therapeutic product.
Cerus Corporation (Nasdaq: CERS) announced a three-year contract with HemoMinas Foundation in Brazil to supply the INTERCEPT Blood System for platelets. HemoMinas, the largest blood service in Minas Gerais, distributes around 25,000 platelet doses annually. The INTERCEPT system is vital for reducing pathogen risks including Zika and Dengue viruses. This contract underscores the importance of pathogen reduction in Brazil's blood safety strategy. The INTERCEPT system is the only one approved by ANVISA for commercial use in the country, supporting over 3.7 million collected blood components each year.
Cerus Corporation (Nasdaq: CERS) announced a clinical study on the efficacy of INTERCEPT-treated COVID-19 convalescent plasma, presented by Dr. Nina Khanna at the American Society of Hematology Annual Meeting on December 5, 2020. The study, involving 15 patients treated with INTERCEPT CCP, showed a 93.3% survival rate at day 28, compared to 20% in the control group. Conducted in collaboration with various research institutions, the findings highlight the potential of INTERCEPT technology in combating COVID-19 and improving patient outcomes.
Cerus Corporation (Nasdaq: CERS) announced FDA approval for the INTERCEPT Blood System for Cryoprecipitation, used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex, critical for treating massive hemorrhage. This product, effective for up to 5 days at room temperature, holds FDA Breakthrough Device designation, signaling significant potential in emergency care. Cerus plans to launch in select states in 2021 and expand nationally in 2022, contingent on further regulatory approvals. This approval aligns with Cerus' mission to set pathogen reduction as the global standard for transfused blood components.
Cerus Corporation (Nasdaq: CERS) announced participation in two upcoming conferences: the Stifel Virtual Healthcare Conference on November 16 at 1:20 PM ET and the Stephens Annual Investment Conference on November 19 at 3:00 PM ET. Key executives, William ‘Obi’ Greenman and Kevin D. Green, will represent the company. A live webcast will be available on the Investor Relations page of Cerus' website, with replays accessible for about two weeks. Cerus focuses on blood safety technologies through its INTERCEPT Blood System.
Cerus Corporation (Nasdaq: CERS) reported Q3 2020 total revenue of $29.2 million, up 27.8% from $22.8 million year-over-year, driven by robust platelet kit sales in the U.S. and the EMEA region. Product revenue reached $23.6 million, a 31% increase, while government contract revenue rose to $5.6 million, a 15.7% increase. Cash reserves at quarter-end stood at $135.1 million. The company narrowed its 2020 product revenue guidance to $89 million to $91 million, attributing the adjustment to COVID-19's impact on blood supply.
Cerus Corporation (Nasdaq:CERS) will release its third quarter 2020 financial results on October 29, 2020, after market close. A conference call will follow at 4:30 P.M. ET to discuss the results and general business outlook. Investors can access the live webcast via Cerus' Investor Relations page. The INTERCEPT Blood System, which has received CE Mark and FDA approval, is the company's primary focus for ensuring safe blood products. The INTERCEPT Red Blood Cell system is currently in clinical development.
Cerus Corporation (Nasdaq:CERS) has secured an $11.1 million contract with the U.S. FDA to develop next-gen compounds for optimizing pathogen reduction (PR) treatment of whole blood. This initiative aims to enhance blood safety and reduce transfusion-transmitted infections. Cerus' program aligns with FDA's proactive strategies for blood safety, complementing its existing products for platelets and plasma. The potential breakthrough in whole blood PR technology could offer comprehensive safety solutions for transfusable blood components.
Cerus Corporation (Nasdaq:CERS) announced notable participation at the AABB 2020 Virtual Annual Meeting, taking place from October 3-5. The event will highlight vital advancements in transfusion medicine, including 17 abstracts presented by Cerus, featuring one oral presentation on optimizing platelet supply. Key focus areas include new FDA guidance on bacterial risk control for platelets and the economic impacts of implementing INTERCEPT Blood System strategies. Cerus remains committed to improving blood safety and is poised for advancements in its clinical studies.
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
What is Cerus Corporation's main focus?
What pathogens does the INTERCEPT Blood System target?
Where is the INTERCEPT Blood System marketed?
What products does Cerus Corporation offer?
What are some recent achievements of Cerus Corporation?
How does the INTERCEPT Blood System work?
What financial strategies does Cerus Corporation employ?
Is Cerus Corporation involved in research for emerging pathogens?
What regions are key markets for Cerus Corporation?
What segment does Cerus Corporation operate in?
